Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotechnology company that regularly reports on progress in its programs for severe autoimmune and inflammatory diseases. News about Dianthus often centers on clinical trial milestones, data readouts, licensing transactions, and capital markets activity related to its investigational therapies.
The company’s updates frequently highlight developments for claseprubart (DNTH103), an investigational monoclonal antibody targeting the classical complement pathway via active C1s inhibition, and DNTH212, an investigational bifunctional fusion protein targeting BDCA2 and BAFF/APRIL. Press releases describe Phase 2 and Phase 3 studies in neuromuscular indications such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, as well as early-stage work in systemic lupus erythematosus through a Phase 1 trial of DNTH212.
Investors and followers of DNTH news can expect coverage of clinical data presentations at medical meetings, initiation and progress of Phase 1, Phase 2, and Phase 3 trials, and regulatory milestones such as investigational new drug clearances. Company communications also include announcements of public offerings of common stock and pre-funded warrants, license and collaboration agreements with partners like Nanjing Leads Biolabs, and participation in healthcare and investor conferences.
This news feed aggregates these disclosures so readers can track how Dianthus advances its investigational complement and immune pathway therapies, how its pipeline evolves, and how financing and partnerships support ongoing development. For those monitoring DNTH, recurring themes include neuromuscular disease programs, complement biology, bifunctional immune modulation, and the company’s positioning as a clinical-stage biotech focused on severe autoimmune conditions.
Dianthus Therapeutics announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology, held in Helsinki from June 29 to July 2, 2024. DNTH103 is an investigational inhibitor targeting the active form of C1s, being evaluated for the treatment of severe neuromuscular conditions like generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy. The presentations will showcase preclinical and in vitro data, highlighting DNTH103's potential advantages over existing treatments. The CEO emphasized DNTH103's potential for safer, more convenient administration with consistent symptom control and fewer risks compared to current therapies.
Dianthus Therapeutics has received FDA clearance to start a Phase 2 trial for DNTH103 in treating Multifocal Motor Neuropathy (MMN). This trial, named the MoMeNtum study, will assess the safety, tolerability, and efficacy of DNTH103 in 36 patients globally. The trial will follow a randomized, double-blind, placebo-controlled design, with patients receiving subcutaneous injections every two weeks for 17 weeks, followed by a 52-week open-label extension. Top-line results are expected in the second half of 2026. DNTH103, a potent C1s inhibitor, aims to offer a more convenient treatment option than current therapies. Dianthus is also building a neuromuscular franchise with planned trials in generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy in 2024.
Dianthus Therapeutics, a biotechnology company focused on antibody complement therapeutics for autoimmune diseases, will participate in the Jefferies Global Healthcare Conference.
The company’s CEO, Marino Garcia, will present a corporate overview on June 6, 2024, at 1:30 p.m. ET in New York.
A live webcast of the presentation will be accessible via the Investors section of Dianthus Therapeutics' website.
Dianthus Therapeutics, a clinical-stage biotech company, reported financial results for Q1 2024, highlighting the initiation of Phase 2 MaGic trial for gMG using DNTH103, with ongoing trials in MMN and CIDP. The company raised $377 million in cash through successful financing, projecting runway till 2027.
Dianthus Therapeutics, a clinical-stage biotechnology company, will participate in the Bank of America Securities 2024 Health Care Conference. The CEO will present a corporate overview, focusing on antibody complement therapeutics for severe autoimmune diseases.
Dianthus Therapeutics, Inc. announced the granting of equity awards to two new non-executive employees as inducements for their employment. The awards comprised non-qualified stock options for a total of 52,000 shares, with a 10-year term and an exercise price of $22.53 per share. The options vest gradually over a 3-year period, subject to specific conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Dianthus Therapeutics (DNTH)?
What is the market cap of Dianthus Therapeutics (DNTH)?
